| Name | BML-284 |
| Description | BML-284 (Wnt agonist 1) is a potent, selective and , cell-permeable Wnt signaling activator. |
| In vitro | Wnt agonist 1 does not inhibit the activity of GSK-3β, and may be a useful tool in the study of physiological processes that involve the Wnt pathway. [1] |
| In vivo | In a Xenopus model, Wnt agonist 1 (10 μM) mimics the effects of Wnt at the whole-organism level, and affects Xenopus embryonic head specification. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.71 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 255 mg/mL (727.8 mM), Sonication is recommended.
|
| Keywords | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | TCF | N-cadherin | MNK45 | malformed phenotype | Inhibitor | inhibit | E-cadherin | cardiac defect | BML-284 | BML284 | BML 284 | beta-catenin | betacatenin | bcatenin | AGS |
| Inhibitors Related | Chlorquinaldol | Urea | Wnt pathway activator 1 | Neohesperidin | XAV-939 | Ethyl linoleate | Monensin sodium salt | Nimbolide | Isoquercetin | (±)-Nornicotine | Methyl Vanillate | Bisdemethoxycurcumin |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Osteogenesis Compound Library | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Anti-Obesity Compound Library | Neuroprotective Compound Library | Anti-Fibrosis Compound Library | Stem Cell Differentiation Compound Library | Bioactive Compounds Library Max | Cytoskeletal Signaling Pathway Compound Library |